Adrenocortical carcinoma other imaging studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
*MIBG scan | *MIBG scan | ||
*[[Bone scan]]s are used to visualize bone [[metastasis]] | *[[Bone scan]]s are used to visualize bone [[metastasis]] | ||
with intense FDG uptake | ==== FDG PET/CT ==== | ||
* ACC presents as a large, heterogeneous mass with intense [[FDG]] uptake.<ref name="pmid22737189" /> | |||
* [[FDG]] [[PET scan|PET/CT]] had a [[Sensitivity (tests)|sensitivity]] of 100% and [[Specificity (tests)|specificity]] of 88% in distinguishing [[benign]] from [[malignant]] lesions by using cutoff value above 1.45 for [[Adrenal gland|adrenal]] to [[liver]] maximum standardized uptake value (SUV). | |||
* [[PET scan|PET/CT]] cannot distinguish ACC from [[Metastasis|metastases]], [[lymphoma]], or [[pheochromocytoma]] due to the high metabolic activity of these tumors.<ref name="pmid22737189">{{cite journal| author=Sundin A| title=Imaging of adrenal masses with emphasis on adrenocortical tumors. | journal=Theranostics | year= 2012 | volume= 2 | issue= 5 | pages= 516-22 | pmid=22737189 | doi=10.7150/thno.3613 | pmc=3364557 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22737189 }}</ref> | |||
* [[FDG]] [[PET scan|PET/CT]] is a useful modality for staging ACC and evaluating local recurrence. | |||
* Increased uptake of [[FDG]] may be seen in benign conditions including postoperative changes. | |||
of 100% and specificity of 88% in distinguishing | * No significant difference in [[Accuracy and precision|accuracy]] was found between visual analysis, SUV analysis, and standardized uptake ratio (defined as the ratio of adrenal SUV activity to liver SUV activity) analysis.<ref name="pmid18397978">{{cite journal| author=Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H et al.| title=[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. | journal=J Clin Endocrinol Metab | year= 2008 | volume= 93 | issue= 6 | pages= 2358-65 | pmid=18397978 | doi=10.1210/jc.2008-0050 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18397978 }}</ref> | ||
* The sensitivity of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for diagnostic [[Computed tomography|CT]]. | |||
benign from malignant lesions by using cutoff value above | * [[FDG]] [[PET scan|PET/CT]] has low [[sensitivity]] for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.<ref name="pmid16621901">{{cite journal| author=Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ et al.| title=Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 7 | pages= 2665-71 | pmid=16621901 | doi=10.1210/jc.2005-2612 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16621901 }}</ref> | ||
* Intensity of [[FDG]] uptake was found to be related to survival in patients with ACC, with a maximum SUV of >10 indicating a poor prognosis.<ref name="pmid16621901" /> | |||
1.45 for adrenal to liver maximum standardized uptake | |||
value (SUV). | |||
cannot distinguish ACC from metastases, lymphoma, | |||
or pheochromocytoma | |||
metabolic activity | |||
PET/CT for | |||
was found between visual analysis, SUV analysis, | |||
and standardized uptake ratio (defined as ratio of adrenal | |||
SUV activity to liver SUV activity) analysis. | |||
[ | |||
diagnosis of metastases as compared with 88% for diagnostic | |||
CT. | |||
characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter | |||
with ACC, with a maximum SUV of | |||
prognosis | |||
==References== | ==References== | ||
Revision as of 17:49, 20 September 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma other imaging studies On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma other imaging studies |
|
Risk calculators and risk factors for Adrenocortical carcinoma other imaging studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
Adrenal angiography,venography, positron emission tomography and MIBG may be used in the diagnosis of adrenocortical carcinoma.
Other Imaging Studies
Other Imaging studies that may be used in diagnosis of adrenocortical carcinoma are:[1]
- Adrenal angiography
- Adrenal venography
- PET scan (positron emission tomography scan)
- MIBG scan
- Bone scans are used to visualize bone metastasis
FDG PET/CT
- ACC presents as a large, heterogeneous mass with intense FDG uptake.[2]
- FDG PET/CT had a sensitivity of 100% and specificity of 88% in distinguishing benign from malignant lesions by using cutoff value above 1.45 for adrenal to liver maximum standardized uptake value (SUV).
- PET/CT cannot distinguish ACC from metastases, lymphoma, or pheochromocytoma due to the high metabolic activity of these tumors.[2]
- FDG PET/CT is a useful modality for staging ACC and evaluating local recurrence.
- Increased uptake of FDG may be seen in benign conditions including postoperative changes.
- No significant difference in accuracy was found between visual analysis, SUV analysis, and standardized uptake ratio (defined as the ratio of adrenal SUV activity to liver SUV activity) analysis.[3]
- The sensitivity of FDG PET/CT was 90% for the diagnosis of metastases as compared with 88% for diagnostic CT.
- FDG PET/CT has low sensitivity for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.[4]
- Intensity of FDG uptake was found to be related to survival in patients with ACC, with a maximum SUV of >10 indicating a poor prognosis.[4]
References
- ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq#section/_1
- ↑ 2.0 2.1 Sundin A (2012). "Imaging of adrenal masses with emphasis on adrenocortical tumors". Theranostics. 2 (5): 516–22. doi:10.7150/thno.3613. PMC 3364557. PMID 22737189.
- ↑ Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H; et al. (2008). "[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes". J Clin Endocrinol Metab. 93 (6): 2358–65. doi:10.1210/jc.2008-0050. PMID 18397978.
- ↑ 4.0 4.1 Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ; et al. (2006). "Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma". J Clin Endocrinol Metab. 91 (7): 2665–71. doi:10.1210/jc.2005-2612. PMID 16621901.